the pathway to uroradiology
TRANSCRIPT
![Page 1: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/1.jpg)
![Page 2: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/2.jpg)
![Page 3: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/3.jpg)
![Page 4: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/4.jpg)
CT
• Stronger X-Ray.
• Rotating Tube.
• A Row of Detectors.
![Page 5: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/5.jpg)
![Page 6: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/6.jpg)
![Page 7: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/7.jpg)
MDCT
![Page 8: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/8.jpg)
MDCT
![Page 9: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/9.jpg)
MPR
![Page 10: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/10.jpg)
![Page 11: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/11.jpg)
![Page 12: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/12.jpg)
Precontrast (non-contrast)
![Page 13: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/13.jpg)
Arterial phase
![Page 14: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/14.jpg)
Venous phase
![Page 15: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/15.jpg)
Nephrographic phase
![Page 16: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/16.jpg)
Delayed phase
![Page 17: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/17.jpg)
Non-Contrast →
![Page 18: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/18.jpg)
Non-Contrast + Nephrographic Phase +/-
Delayed Phase →
![Page 19: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/19.jpg)
Non-Contrast + Arterial Phase +/- venous
Phase →
![Page 20: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/20.jpg)
Non-Contrast + Excretory Phase →
![Page 21: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/21.jpg)
Non-Contrast + Arterial Phase + venous
Phase + Nephrographic Phase + Delayed
Phase →
![Page 22: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/22.jpg)
![Page 23: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/23.jpg)
![Page 24: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/24.jpg)
![Page 25: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/25.jpg)
![Page 26: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/26.jpg)
![Page 27: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/27.jpg)
Pathology 1
Pathology 2
Pathology 3
T1 T2
![Page 28: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/28.jpg)
![Page 29: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/29.jpg)
![Page 30: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/30.jpg)
![Page 31: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/31.jpg)
• Prostate
• Urinary bladder
• Kidneys
• Testis
• Adrenal Gland
![Page 32: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/32.jpg)
• Diagnosis of carcinoma + Local Staging
![Page 33: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/33.jpg)
• Conventional MRI
• Dynamic MRI
• MRI Diffusion
• MR Spectroscopy
![Page 34: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/34.jpg)
![Page 35: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/35.jpg)
![Page 36: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/36.jpg)
![Page 37: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/37.jpg)
![Page 38: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/38.jpg)
![Page 39: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/39.jpg)
![Page 40: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/40.jpg)
![Page 41: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/41.jpg)
![Page 42: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/42.jpg)
![Page 43: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/43.jpg)
![Page 44: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/44.jpg)
![Page 45: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/45.jpg)
![Page 46: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/46.jpg)
![Page 47: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/47.jpg)
![Page 48: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/48.jpg)
![Page 49: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/49.jpg)
![Page 50: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/50.jpg)
![Page 51: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/51.jpg)
![Page 52: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/52.jpg)
![Page 53: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/53.jpg)
![Page 54: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/54.jpg)
![Page 55: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/55.jpg)
• MRI can be useful in the evaluation of scrotal
masses as a problem-solving technique:
1. Discrepancies between US and clinical
findings.
2. Diffuse, non-specific testicular
involvement seen on US scanning.
3. Fibrous lesions, lipomas or hemorrhage
are suspected.
![Page 56: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/56.jpg)
![Page 57: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/57.jpg)
![Page 58: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/58.jpg)
![Page 59: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/59.jpg)
G 18FDG
hexokinase
Glucose 6 Phosphate
18FDG 6 Phosphate
Fructose 6 Phosphate
Pyruvate
Anaerobic resp Citric acid cycle
Blood vessel
Cell
![Page 60: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/60.jpg)
![Page 61: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/61.jpg)
![Page 62: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/62.jpg)
• Prostate cancer
• Urinary bladder cancer
• Renal cancer
• Testicular cancer
![Page 63: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/63.jpg)
The use of FDG-PET in the diagnosis of localized prostate
cancer has proven to be disappointing primarily because :
1- False-positive: excreted FDG activity accumulating in the ureters and
bladder may limit the evaluation of adjacent structures such as the
prostate and pelvic lymph nodes.
2- False-negative: most prostate cancers have a relatively low glycolytic
rate and therefore do not accumulate high concentrations of the
radiotracer FDG.
![Page 64: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/64.jpg)
Detection of localized prostate cancer with FDGPET is
hampered by the inherently low metabolic activity of
malignant cells found in these tumors. As a result, the
relatively low tracer uptake by localized prostate cancer is
difficult to delineate from that of tissue found in benign
prostatic hyperplasia.
![Page 65: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/65.jpg)
The most promising indication for PET with regard to
prostate cancer lies in its ability to evaluate changes in
tumor burden and location of disease during therapy and,
thus, to determine the prognosis of the patient.
![Page 66: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/66.jpg)
![Page 67: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/67.jpg)
As with prostate cancer, the use of PET in the context of bladder cancer is significantly limited because of the urinary excretion of FDG and subsequent poor differentiation of lesions in the bladder and adjacent lymph nodes. Nonetheless, PET has been demonstrated to identify both local and distant spread of bladder cancer with some success.
![Page 68: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/68.jpg)
PET has also been implemented in the
diagnosis and monitoring progression of
treated RCC in the form of local recurrence
or metastasis.
![Page 69: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/69.jpg)
![Page 70: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/70.jpg)
![Page 71: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/71.jpg)
![Page 72: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/72.jpg)
PET, therefore, is a valuable tool in the diagnosis and
management of RCC. While demonstrating at least
equivalent accuracy in diagnosing primary RCC when
compared with CT, the current gold standard, PET appears
to be more accurate in monitoring for progression of
disease, metastasis, or local recurrence in the renal fossa
bed. At the very least, PET appears to be a useful adjunct to
conventional imaging in the management of RCC.
![Page 73: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/73.jpg)
One limitation of PET in these studies was its inability to
detect metastatic lesions less than 5 mm in diameter. This is
also a limitation of CT scanning, which is unable to
accurately diagnose lymph node metastases until the nodal
size reaches 1 cm. In addition, PET was limited by its low
sensitivity for detecting mature teratoma, which has a low
glucose metabolic rate.
![Page 74: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/74.jpg)
Another diagnostic challenge in the management of
testicular cancer is the postchemotherapy evaluation of a
residual mass in the retroperitoneum. The differentiation
between residual tumor, fibrosis, and teratoma can play a
significant role in guiding further therapy.
![Page 75: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/75.jpg)
Studies evaluating PET in this setting have demonstrated
sensitivities ranging from 79% to 87% and specificities from
90% to 94%.
![Page 76: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/76.jpg)
![Page 77: The pathway to uroradiology](https://reader033.vdocuments.mx/reader033/viewer/2022052514/5a6d2fd17f8b9aff418b4f37/html5/thumbnails/77.jpg)